Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab in Recurrent or Refractory Active Chronic Graft Versus Host Disease
NCT04710576Phase 2Recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 2 trial of axatilimab in chronic graft-versus-host disease (cGVHD), sponsored by Syndax Pharmaceuticals. Started Mar 2021; status: recruiting.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04710576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04710576.